000			02822nam a22003137a 4500
003			OSt
005			20240305193719.0
008			221101b |||||||| |||| 00| 0 eng d
028			_b Phone: +255 28 298 3384
028			_b Fax: +255 28 298 3386
028			_b Email: vc@bugando.ac.tz
028			_bWebsite: www.bugando.ac.tz
040			_cdlc
041			_aMwanza
100			_aKarol J Marwa _922958
222			_aLumefantrine day 7 concentration day 3 concentration treatment outcomes and Tanzania
245			_aLumefantrine plasma concentrations in uncontrolled conditions among patients treated with artemether-lumefantrine for uncomplicated plasmodium falciparum malaria in Mwanza, Tanzania
260			_aMwanza _bElsevier & _bTanzania Catholic University of Health and Allied Sciences [CUHAS – Bugando] _cOctober 2022
300			_a Pages 192-199
490			_vInternational Journal of Infectious Diseases Volume 123
520			_aAbstract Background Therapeutic efficacy of artemether-lumefantrine is highly dependent on adequate systemic exposure to the partner drug lumefantrine particularly day 7 lumefantrine plasma concentration. There has been contradicting findings on the role of the cut-off values in predicting treatment outcomes among malaria patients in malaria endemic regions. This study assesses the day 3 and 7 lumefantrine plasma concentrations including related determinant factors and their influence on treatment outcomes among treated Tanzanian children and adults in uncontrolled conditions (real life condition). Methods Data was nested from an efficacy study employing the WHO protocol, 2015 for monitoring antimalarial drug efficacy. Lumefantrine plasma concentration was measured by high performance liquid chromatography with ultraviolet (HPLC-UV). Results: Lumefantrine plasma concentrations below 175ng/ml and 200ng/ml on day 3 and 7 did not affect adequate clinical and parasitological response (ACPR) and recurrence of infection (p = 0.428 and 0.239 respectively). Age and baseline parasitemia were not associated to day 3 median lumefantrine plasma concentrations (p = 0.08 and 0.31 respectively) and day 7 lumefantrine plasma concentrations (p = 0.07 and 0.41 respectively). However, the day 3 and day 7 lumefantrine plasma concentrations were significantly higher in males compared to females (p = 0.03 and 0.042 respectively). Conclusion Lumefantrine plasma concentrations below cut-off points (175ng/ml and 200ng/ml) on day 3 and 7 did not influence treatment outcomes.
700			_a Anthony C Liwa _923052
700			_aEveline T Konje _923135
700			_a Stanley Mwita _922957
700			_aErasmus Kamugisha _922814
700			_a Göte Swedberg _944911
856			_uhttps://doi.org/10.1016/j.ijid.2022.08.020
942			_2ddc _cVM
999			_c19217 _d19217